This document is scheduled to be published in the Federal Register on 06/19/2019 and available online at https://federalregister.gov/d/2019-13027, and on govinfo.gov

[Billing Code: 4140-01-P]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Mobile Technologies Extending Reach of Primary Care for Substance-

Use-Disorders (R41/R42/R43/R44 - Clinical Trial Optional)

Date: June 14, 2019

Time: 12:00 PM to 5:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center Building (NSC)

6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

Contact Person: Ipolia R. Ramadan, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

Division of Extramural Research

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Boulevard, Room 4228, MSC 9550

Bethesda, MD 20892

301-827-5842

ramadanir@mail.nih.gov

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Evaluating the NIDA Standardized Research E-Cigarette in Risk Reduction and Related Studies (U01 Clinical Trial Optional)

Date: June 21, 2019

Time: 11:00 AM to 2:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health

Neuroscience Center Building (NSC)

6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

Contact Person: Ipolia R. Ramadan, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

Division of Extramural Research

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Boulevard, Room 4228, MSC 9550

Bethesda, MD 20892

301-827-5842

ramadanir@mail.nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Identification of Genetic and Genomic Variants by Next-Gen Sequencing

in Non-human Animal Models (U01)

Date: June 28, 2019

Time: 11:00 AM to 5:00 PM

Agenda: To review and evaluate cooperative agreement applications

Place: National Institutes of Health

Neuroscience Center Building (NSC)

6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

Contact Person: Ipolia R. Ramadan, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

Division of Extramural Research

National Institute on Drug Abuse, NIH, DHHS 6001 Executive Boulevard, Room 4228, MSC 9550

Bethesda, MD 20892

301-827-5842

ramadanir@mail.nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel

Device-Based Treatments for Substance Use Disorders (UH2/UH3)

(Clinical Trial Optional)

Date: July 9, 2019

Time: 10:00 AM to 11:00 AM

Agenda: To review and evaluate cooperative agreement applications

Place: National Institutes of Health

Neuroscience Center Building (NSC)

6001 Executive Boulevard Rockville, MD 20852

(Telephone Conference Call)

Contact Person: Susan O. McGuire, Ph.D.

Scientific Review Officer

Office of Extramural Policy and Review

National Institute on Drug Abuse National Institutes of Health, DHHS 6001 Executive Blvd., Room 4245

Rockville, MD 20852

(301) 827-5817

mcguire so@mail.nih.gov

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: June 14, 2019.

\_\_\_\_\_

Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-13027 Filed: 6/18/2019 8:45 am; Publication Date: 6/19/2019]